National Advertising Division Recommends i-Health Discontinue Health-Related Claims for Culturelle IBS Complete Support
Retrieved on:
Tuesday, May 31, 2022
Human, USE, IBS, Quality of life, Constipation, Procter & Gamble, P&G, Abdominal pain, Bloating, Food, Multimedia, Patient, Bacteria, Health, Better Business Bureau, Probiotic, HMO, Water, Clinical trial, Privacy, Failure, Diarrhea, Trial of the century, CARU, FDA, Council, Dietary management, Irritability, Nutritional science, Advertising, Association of National Advertisers, Irritable bowel syndrome, NAD, Pharmaceutical industry, Dietary supplement, Dairy product, Lactobacillus rhamnosus
NEW YORK, May 31, 2022 /PRNewswire/ --The National Advertising Division (NAD) of BBB National Programs recommended that i-Health, Inc. (DSM North America) discontinue health-related claims for its Culturelle IBS Complete Support, including:
Key Points:
- NEW YORK, May 31, 2022 /PRNewswire/ --The National Advertising Division (NAD) of BBB National Programs recommended that i-Health, Inc. (DSM North America) discontinue health-related claims for its Culturelle IBS Complete Support, including:
The claim "IBS Complete Support" in the product name; and
Claims that convey a message that the product provides specific symptom relief benefits due to its status as a medical food. - Culturelle IBS is labeled and marketed as a medical food for the nutritional management of IBS and IBS-related symptoms.
- NAD noted that the advertiser's claims that Culturelle IBS has been "clinically shown" to provide benefits to IBS sufferers are "establishment" claims, which promise the consumer that scientific evidence proves or "establishes" the truth of its claims.
- "Culturelle IBS Complete Support helps you nutritionally manage your symptoms, such as bloating, constipation, diarrhea, and abdominal pain."